复发或残留垂体腺瘤伽玛刀放射手术后的长期肿瘤控制：一项基于人群的队列研究

IF 1.9 3区医学 Q3 CLINICAL NEUROLOGY Acta Neurochirurgica Pub Date : 2024-11-30 DOI:10.1007/s00701-024-06380-9

Alexander Gabri, Felicia Lindberg, Helena Kristiansson, Michael Gubanski, Charlotte Höybye, Martin Olsson, Petter Förander, Simon Skyrman, Bodo Lippitz, Alexander Fletcher-Sandersjöö, Jiri Bartek

{"title":"复发或残留垂体腺瘤伽玛刀放射手术后的长期肿瘤控制：一项基于人群的队列研究","authors":"Alexander Gabri, Felicia Lindberg, Helena Kristiansson, Michael Gubanski, Charlotte Höybye, Martin Olsson, Petter Förander, Simon Skyrman, Bodo Lippitz, Alexander Fletcher-Sandersjöö, Jiri Bartek","doi":"10.1007/s00701-024-06380-9","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Pituitary adenomas (PAs) often require adjuvant Gamma Knife radiosurgery (GKRS) due to partial resection or postoperative recurrence. The purpose of this study was to evaluate the long-term efficacy of GKRS for such cases.</p><h3>Methods</h3><p>Population-based, observational cohort study of patients who underwent GKRS for postoperative residual or recurrent PAs between 1999 and 2020. We assessed long-term progression-free survival (PFS), identified predictors of tumor growth, and documented adverse radiation events (AREs).</p><h3>Results</h3><p>147 patients were included, with a median follow-up time of 8.1 years. Following GKRS, the 5-year and 10-year PFS was 86% and 68%, respectively, with a median PFS of 18.7 years. Somatotrophic adenomas showed a significantly lower risk of tumor progression in the regression analysis (OR 0.11, <i>p</i> = 0.003). Hypopituitarism was the most common ARE, affecting 32% of patients.</p><h3>Conclusion</h3><p>GKRS is an effective treatment option for recurrent or residual PAs, offering substantial long-term control. However, the risk for AREs, particularly hypopituitarism, is not negligeable.</p></div>","PeriodicalId":7370,"journal":{"name":"Acta Neurochirurgica","volume":"166 1","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00701-024-06380-9.pdf","citationCount":"0","resultStr":"{\"title\":\"Long-term tumor control following gamma-knife radiosurgery of recurrent or residual pituitary adenomas: a population-based cohort study\",\"authors\":\"Alexander Gabri, Felicia Lindberg, Helena Kristiansson, Michael Gubanski, Charlotte Höybye, Martin Olsson, Petter Förander, Simon Skyrman, Bodo Lippitz, Alexander Fletcher-Sandersjöö, Jiri Bartek\",\"doi\":\"10.1007/s00701-024-06380-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Pituitary adenomas (PAs) often require adjuvant Gamma Knife radiosurgery (GKRS) due to partial resection or postoperative recurrence. The purpose of this study was to evaluate the long-term efficacy of GKRS for such cases.</p><h3>Methods</h3><p>Population-based, observational cohort study of patients who underwent GKRS for postoperative residual or recurrent PAs between 1999 and 2020. We assessed long-term progression-free survival (PFS), identified predictors of tumor growth, and documented adverse radiation events (AREs).</p><h3>Results</h3><p>147 patients were included, with a median follow-up time of 8.1 years. Following GKRS, the 5-year and 10-year PFS was 86% and 68%, respectively, with a median PFS of 18.7 years. Somatotrophic adenomas showed a significantly lower risk of tumor progression in the regression analysis (OR 0.11, <i>p</i> = 0.003). Hypopituitarism was the most common ARE, affecting 32% of patients.</p><h3>Conclusion</h3><p>GKRS is an effective treatment option for recurrent or residual PAs, offering substantial long-term control. However, the risk for AREs, particularly hypopituitarism, is not negligeable.</p></div>\",\"PeriodicalId\":7370,\"journal\":{\"name\":\"Acta Neurochirurgica\",\"volume\":\"166 1\",\"pages\":\"\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-11-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://link.springer.com/content/pdf/10.1007/s00701-024-06380-9.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Neurochirurgica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s00701-024-06380-9\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Neurochirurgica","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s00701-024-06380-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景垂体腺瘤（PAs）由于部分切除或术后复发，通常需要辅助伽玛刀放射手术（GKRS）。本研究的目的是评估GKRS对此类病例的长期疗效。方法对1999年至2020年间因术后残留或复发性PAs接受GKRS的患者进行基于人群的观察性队列研究。我们评估了长期无进展生存期（PFS），确定了肿瘤生长的预测因素，并记录了不良辐射事件（AREs）。结果147例患者入组，中位随访时间8.1年。GKRS后，5年和10年PFS分别为86%和68%，中位PFS为18.7年。在回归分析中，生长营养腺瘤的肿瘤进展风险显著降低（OR 0.11, p = 0.003）。垂体功能减退是最常见的ARE，影响32%的患者。结论krs是复发性或残余PAs的有效治疗方案，具有良好的长期控制作用。然而，阿瑞斯的风险，特别是垂体功能减退，是不可忽视的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Long-term tumor control following gamma-knife radiosurgery of recurrent or residual pituitary adenomas: a population-based cohort study

Background

Pituitary adenomas (PAs) often require adjuvant Gamma Knife radiosurgery (GKRS) due to partial resection or postoperative recurrence. The purpose of this study was to evaluate the long-term efficacy of GKRS for such cases.

Methods

Population-based, observational cohort study of patients who underwent GKRS for postoperative residual or recurrent PAs between 1999 and 2020. We assessed long-term progression-free survival (PFS), identified predictors of tumor growth, and documented adverse radiation events (AREs).

Results

147 patients were included, with a median follow-up time of 8.1 years. Following GKRS, the 5-year and 10-year PFS was 86% and 68%, respectively, with a median PFS of 18.7 years. Somatotrophic adenomas showed a significantly lower risk of tumor progression in the regression analysis (OR 0.11, p = 0.003). Hypopituitarism was the most common ARE, affecting 32% of patients.

Conclusion

GKRS is an effective treatment option for recurrent or residual PAs, offering substantial long-term control. However, the risk for AREs, particularly hypopituitarism, is not negligeable.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Acta Neurochirurgica 医学-临床神经学

CiteScore

4.40

自引率

4.20%

发文量

342

审稿时长

1 months

期刊介绍： The journal "Acta Neurochirurgica" publishes only original papers useful both to research and clinical work. Papers should deal with clinical neurosurgery - diagnosis and diagnostic techniques, operative surgery and results, postoperative treatment - or with research work in neuroscience if the underlying questions or the results are of neurosurgical interest. Reports on congresses are given in brief accounts. As official organ of the European Association of Neurosurgical Societies the journal publishes all announcements of the E.A.N.S. and reports on the activities of its member societies. Only contributions written in English will be accepted.